| Year |
Citation |
Score |
| 2014 |
Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 123: 632-9. PMID 24335104 DOI: 10.1182/blood-2013-05-504340 |
0.313 |
|
| 2012 |
Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leukemia & Lymphoma. 53: 1174-82. PMID 22054286 DOI: 10.3109/10428194.2011.637212 |
0.376 |
|
| 1998 |
Mulligan G, Jacks T. The retinoblastoma gene family: cousins with overlapping interests. Trends in Genetics : Tig. 14: 223-9. PMID 9635405 DOI: 10.1016/S0168-9525(98)01470-X |
0.587 |
|
| 1996 |
Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D, Weinberg RA, Jacks T. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes & Development. 10: 1633-44. PMID 8682294 DOI: 10.1101/Gad.10.13.1633 |
0.586 |
|
| 1996 |
Lee MH, Williams BO, Mulligan G, Mukai S, Bronson RT, Dyson N, Harlow E, Jacks T. Targeted disruption of p107: functional overlap between p107 and Rb. Genes & Development. 10: 1621-32. PMID 8682293 DOI: 10.1101/Gad.10.13.1621 |
0.54 |
|
| Show low-probability matches. |